The global hospital-acquired infection treatment market is expected to reach US$ 19,978.39 million in 2030 from US$ 15,099.19 million in 2022. The market is estimated to grow with a CAGR of 3.6% from 2022 to 2030.
The key factors driving the market’s growth include the high prevalence of hospital-acquired infections (HAI) and the growing focus on patient safety and quality care. However, the threat of antimicrobial resistance hinders market growth
Market Drivers of the Hospital-Acquired Infection Treatment Market
Central line-associated bloodstream infections, catheter-associated urinary tract infections, and ventilator-associated pneumonia are a few examples of healthcare-associated infections (HAIs). These infections can also arise at surgical sites. According to the Centers for Disease Control and Prevention (CDC) report “2020 National and State Healthcare-Associated Infections Progress Report” published in 2021, cases of central line-associated bloodstream infections, Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia, and ventilator-associated events increased by 24%, 35%, and 15%, respectively, in the US between 2019 and 2020.
Avail Sample PDF Copy @ https://www.theinsightpartners.com/sample/TIPRE00029976/
Furthermore, According to the January 2022 report from the National Healthcare Safety Network (NHSN), urinary tract infections (UTIs) are the fifth most common type of healthcare-associated infection. UTIs account for more than 9.5% of acute care hospital conditions. Catheter-associated urinary Tract Infection (CAUTI) is caused by urinary catheters used to drain urine from the bladder. CAUTI is one of the most frequent infections among hospitalized UTI patients. According to the Centers for Disease Control and Prevention (CDC), nearly 75% of infections are related to a urinary catheter. During hospital stays, 15% to 25% of hospitalized patients must use urinary catheters. Prolonged urinary catheter use is the most major risk factor for getting CAUTI. CAUTI complications entail patient suffering, prolonged hospital stays, increased treatment costs, and even death.
Hospital Acquired Infection Treatment Market: Segmental Overview
The hospital acquired infection treatment market, by drug class, is segmented into antibacterial, antiviral, antifungal, and others. The antibacterial drugs segment held the largest market share in 2022 and is anticipated to register the highest CAGR during 2022–2030.
The hospital acquired infection treatment market, by infection type, is segmented into urinary tract infections, ventilator-associated pneumonia, surgical site infections, bloodstream infections, and other hospital infections. The urinary tract infections segment held the largest market share in 2022. However, the ventilator-associated pneumonia segment is anticipated to register the highest CAGR from 2022 to 2030.
About Us:
The Insight Partners is a market research solution and consultation company. Specializing in syndicate market research, our team helps clients in their hunt for revenue pockets in several industries. A team of 250+ research experts is dedicated to offering the most relevant, data-driven, and trustworthy market insights and consultation.
Contact Us:
If you have any queries about this report or if you would like further information, please contact us
The Insight Partners
Phone: +1-646-491-9876
E-mail: [email protected]
About Author
